New insight on the correlation of immune landscapes with immune markers expression in different risk classification of gastrointestinal stromal tumors
- 24 March 2023
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 58 (6) , 527-539
Abstract
Background The immune landscapes of gastrointestinal stromal tumors (GISTs) are still unclear. We aimed to explore the immune status of GISTs with different recurrence risks and sought potential immunotherapeutic targets. Methods Immune cell infiltration and the expression of 93 tumor markers of 65 GISTs with different recurrence risks from public datasets were analyzed via bioinformatic methods. Infiltrating immune cell and OX40L expression of 417 patients from the Zhongshan cohort were analyzed by immunohistochemistry and immunofluorescence. The clinicopathological data of the patients were collected and the prognostic factors were analyzed by univariate and multivariate methods. Results Macrophages, T cells and NK cells were the most abundant immune cells in tumor microenvironment. OX40L was the only differentially expressed marker in high- and low-risk patients, as well as in patients with primary and recurrent GIST. The positive rate of OX40L in GIST was 54%. OX40L was highly expressed in patients with no metastasis, low mitotic index and relapse risk. The amount of CD68 + macrophages was the independent factor of OX40L expression. The OX40L expression was positively correlated with M2 and resting mast cells. OX40L co-located with CD4 + T cells, M2 and activated mast cells. Patients with high OX40L levels experienced more prolonged relapse-free survival (RFS). Conclusions We first reported that GIST cells could express OX40L, patients with high OX40L experienced longer RFS. The colocalization of OX40L with immune cells indicates that OX40L could be a promising potential target for immunotherapy in GIST.Keywords
Funding Information
- National Natural Science Foundation of China (82003184, 82071763)
This publication has 39 references indexed in Scilit:
- Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell FunctionThe Journal of Immunology, 2013
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsThe Lancet Oncology, 2012
- Exploiting antitumor immunity to overcome relapse and improve remission durationCancer Immunology, Immunotherapy, 2011
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature Medicine, 2011
- Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumorsInternational Journal of Cancer, 2009
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejectionJournal of Experimental Medicine, 2008
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006
- CD4+CD3− Accessory Cells Costimulate Primed CD4 T Cells through OX40 and CD30 at Sites Where T Cells Collaborate with B CellsImmunity, 2003
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001